Immune Checkpoint Inhibitor Combination (ICI Combination)
Immune checkpoints are a normal part of the immune system. Their role is to prevent an immune response from being so strong that it destroys healthy cells in the body.
Immunotherapy drugs called immune checkpoint inhibitors work by blocking checkpoint proteins from binding with their partner proteins. This prevents the “off” signal from being sent, allowing the T cells to kill cancer cells.
Unfortunately, many cancers do not respond to immune checkpoint inhibitors.
EC-18 is currently in early-stage preclinical studies in combination with immune checkpoint inhibitors to improve the response rate of certain solid cancers.
EC-18’s Mechanism of Action in ICI Combination
EC-18 has exerted antitumor effects of its own, not only in primary tumors but also in metastases. Also, EC-18 has exerted synergistic antitumor effect when combined with cytotoxic chemotherapy. EC-18 is expected to work synergistically with ICI through improving immunosuppressive tumor microenvironment, as demonstrated in animal model.